Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Curesponse Secures Additional Usd 8 Million Funding For Its Breakthrough Precision Oncology Platform
PRIVATENov 15, 2021•almost 5 years ago
Amount Raised
$8 Million
Round Type
Funding Round
Reẖovot
Description
Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform.
Company Information
Company
Curesponse
Location
Reẖovot, Merkaz, Israel
About
The company has raised an additional USD 8 million from leading investors to facilitate scaling of clinical studies and expansion of commercial international footprint. In the recent AACR (American Association of Cancer Research) meeting, the company presented data from its clinical studies where cResponse was compared to the clinical response of patients for which this data is already available. The test has recently become commercially available in Israel and some private insurance companies cover it for their patients. Curesponse is a cancer precision medicine company whose platform, cResponse, accurately and timely predicts a patient's response to cancer treatment.
Don't miss Curesponse's next move
Get an email the moment Curesponse raises, hires an exec, or expands, usually minutes after it happens.